Severe pneumonia caused by combined infection with Pneumocystis carinii, parainfluenza virus type 3, cytomegalovirus and Aspergillus fumigatus in a patient with stevens-johnson syndrome/toxic epidermal necrolysis

Acta Dermato-Venereologica

Volumn 90, Issue 6, 2010, Pages 625-629

  Lee, Taehoon ^a   Bae, Yun Jeong ^a   Park, Soo Kyung ^a   Park, Hyun Jung ^a   Kim, Sung Han ^a   Cho, You Sook ^a   Moon, Hee Bom ^a   Lee, Sang Oh ^a   Kim, Tae Bum ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Corticosteroid; Infection; Pneumonia; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GANCICLOVIR; IMIPENEM; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PRIMAQUINE; RIBAVIRIN; VANCOMYCIN; VORICONAZOLE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; BACTERIUM CULTURE; BLISTER; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; CORTICOSTEROID THERAPY; COUGHING; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSPNEA; ENDOTRACHEAL INTUBATION; FEMALE; FEVER; FUNGUS CULTURE; HOSPITAL DISCHARGE; HUMAN; HYDRATION; HYPEREMIA; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; INTERSTITIAL PNEUMONIA; LUNG LAVAGE; MIXED INFECTION; PARAINFLUENZA VIRUS 3; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PULMONARY REHABILITATION; RASH; RESPIRATORY DISTRESS; STEVENS JOHNSON SYNDROME; THORAX RADIOGRAPHY; THROMBOCYTOSIS; TOTAL PARENTERAL NUTRITION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT OUTCOME; ULCER; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS CULTURE; WOUND CARE; WOUND DRESSING;

ADRENAL CORTEX HORMONES; ALLOPURINOL; ANTI-INFECTIVE AGENTS; ASPERGILLUS FUMIGATUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PARAINFLUENZA VIRUS 3, HUMAN; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PULMONARY ASPERGILLOSIS; RESPIRATION, ARTIFICIAL; RESPIROVIRUS INFECTIONS; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 78649715687     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0977     Document Type: Article

References (26)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285.
2. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008; 122: 992-1000.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96.
4. Tripathi A, Ditto AM, Grammer LC, Grenberger PA, McGrath KG, Zeiss CR, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total seriesof 67 cases. Allergy Asthma Proc 2000; 21: 101-105.
5. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6: 543-549.
6. Patterson R, Grammer LC, Greenberger PA, Lawrence ID, Zeiss CR, Detjen PF, et al. Stevens-Johnson syndrome (SJS): effectiveness of corticosteroids in management and recurrent SJS. Allergy Proc 1992; 13: 89-95.
7. Patterson R, Miller M, Kaplan M, Doan T, Brown J, Detjen P, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994; 73: 27-34.
8. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87: 144-148.
9. Kelemen JJ, Cioffi WG, McManus WF, Mason AD, Pruitt BA. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180: 273-278.
10. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-512.
11. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
12. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607.
13. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
14. Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med 2010; 36: 22-32.
15. Pruitt BA. Burn treatment for the unburned. JAMA 1987; 257: 2207-2208.
16. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns 2010; 36: 152-163.
17. Mayes T, Gottschlich M, Khoury J, Warner P, Kagan R. Energy requirements of pediatric patients with Stevens- Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008; 23: 547-550.
18. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
19. Noskin GA, Patterson R. Outpatient management of Stevens-Johnson syndrome: a report of four cases and management strategy. Allergy Asthma Proc 1997; 18: 29-32.
20. Martinez AE, Atherton DJ. High-dose systemic corticosteroids can arrest recurrences of severe mucocutaneous erythema multiforme. Pediatr Dermatol 2000; 17: 87-90.
21. Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome. Int Ophthalmol Clin 2005; 45: 25-48.
22. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
23. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol 2009; 48: 1122-1128.
24. Mukasa Y, Craven N. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J 2008; 84: 60-65.
25. Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23: 1237-1244.
26. Mandell GL, Bennett JE, Dolin R. Infections in the immunocompromised host: general principles. In: Donnelly JP, De Pauw BE, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 6th edn, vol. 2. Philadelphia: Elsevier; 2005: p. 3421-3432.